"Exciting new compounds to treat bacterial infection"

Prolysis is an antibacterial drug discovery and development company. We are focused on the development of new classes of DNA supercoiling and cell division inhibitors to treat hospital-acquired and community-associated infections.

News

• Prolysis’ discovery of a new class of antibacterials has been published in Science.
  19th September 2008
• Prolysis to present at a Gordon Research Conference in Lucca, Italy
  5th February 2008
• Prolysis receives a £3.48 million Seeding Drug Discovery award from the Wellcome Trust
  15th January 2007
• Prolysis publishes a research paper describing a novel antibacterial target
  12th January 2007
• Prolysis invited to present at Superbugs & Superdrugs conference in London
  24th April 2006